Eledon Pharmaceuticals announced that the U.S. Food and Drug Administration granted orphan drug designation to its investigational anti‑CD40L antibody, tegoprubart, for the prevention of allograft rejection in liver transplantation. The designation applies to a patient population of fewer than 200,000 in the United States, qualifying the indication as a rare disease.
The orphan designation brings seven years of market exclusivity, potential tax credits for qualified clinical‑trial expenses, and fee waivers for marketing applications. These incentives can accelerate development and reduce the cost of bringing tegoprubart to market for liver transplant patients.
Tegoprubart is an anti‑CD40L antibody that Eledon has been developing for kidney transplantation and other organ transplants. The new liver indication expands the drug’s therapeutic portfolio and aligns with the company’s strategy to leverage the platform across multiple transplant settings.
Eledon plans to initiate an investigator‑sponsored trial in liver transplantation later in 2026. The trial will evaluate safety and efficacy in preventing rejection, building on promising preclinical data and early results from kidney transplantation studies.
The designation also marks a strategic milestone for Eledon, which already holds orphan status for kidney transplantation and ALS. The new liver indication broadens the company’s pipeline and could enhance its long‑term commercial prospects. Analysts noted the incentive package and the expansion of the drug’s indication as positive developments for the company.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.